These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29534389)

  • 1. [Analysis of predictive effect of Androgen receptor on the response to neoadjuvant chemotherapy in breast cancer patients].
    Zhu JJ; Jiao DC; Qiao JH; Wang LN; Ma YZ; Lu ZD; Liu ZZ
    Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(8):601-605. PubMed ID: 29534389
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
    Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
    Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy.
    Wasserman JK; Williams PA; Islam S; Robertson SJ
    Pathol Res Pract; 2016 Jun; 212(6):539-44. PubMed ID: 27067807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive factors of pathological complete response in primary human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy].
    Liu S; Xu L; Zhang H; Zhang S; Li T; Duan X; Liu Y
    Zhonghua Wai Ke Za Zhi; 2016 Feb; 54(2):94-8. PubMed ID: 26876074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
    Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
    Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
    Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes].
    Liu Y; Zhang X; Yu F; Liu J; Zhang M; Zhang S; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):671-6. PubMed ID: 25564057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
    Hashimoto Y; Tatsumi S; Takeda R; Naka A; Ogane N; Kameda Y; Kawachi K; Shimizu S; Sakai M; Kamoshida S
    Breast Cancer Res Treat; 2014 May; 145(1):101-11. PubMed ID: 24671357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
    Asano Y; Kashiwagi S; Onoda N; Kurata K; Morisaki T; Noda S; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Br J Cancer; 2016 Jan; 114(1):14-20. PubMed ID: 26757422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.